Skip to Content
 

News: Leukemia

Vanderbilt to host symposium on bone marrow disorders

Sunday, September 17th, 2017

Vanderbilt University Medical Center (VUMC) clinicians will host an educational symposium on bone marrow disorders, including bone marrow failure, acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), on Friday, Oct. 13, from 11:30 a.m. – 6 p.m. at the Omni Nashville Hotel, 250 5th Ave. South.

HDAC3 role in B-cell development

Monday, August 7th, 2017

Histone deacetylases (HDACs) are enzymes that modulate gene expression and have important roles in development and disease. HDAC inhibitors are active against lymphoma, and understanding the roles of specific HDACs is important for further therapeutic development. Scott Hiebert, Ph.D., and colleagues used a mouse model to explore the role of HDAC3 in the early development […]

Restore T cells to fight leukemia

Thursday, September 15th, 2016

Acute and chronic B cell leukemia can promote T cell “exhaustion,” which contributes to increased susceptibility to infection and mortality. The treatment-independent mechanisms by which leukemia promotes T cell dysfunction are poorly understood, however. Since metabolic pathways must be tightly regulated to allow normal T cell proliferation and function, Jeffrey Rathmell, Ph.D., Peter Siska, M.D., […]

Medical staff, theater join forces to help cancer patient see ‘Star Wars’

Thursday, January 21st, 2016

A Vanderbilt patient who has battled leukemia for nearly five years was granted a private screening of “Star Wars: The Force Awakens,” thanks to her medical providers and a local movie theater. Like millions of fans worldwide, Natalie Seale, 22, was excited to see the long-anticipated film, but she is unable to be in large […]

Damon Runyon cancer grant boosts Davila’s research

Thursday, July 23rd, 2015

Marco Davila, M.D., Ph.D., assistant professor of Medicine and of Cancer Biology, has received a grant from the Damon Runyon Cancer Research Foundation that will provide $450,000 over three years to help fund his research on therapies for several types of blood disorders, including various forms of leukemia and non-Hodgkin (also known as non-Hodgkin’s) lymphoma. Davila’s […]

Biochemistry’s Hodges stays grounded in joy of discovery

Thursday, July 16th, 2015

Albert Einstein once wrote, “It is the supreme art of the teacher to awaken joy in creative expression and knowledge.” For Emily Hodges, Ph.D., that awakening occurred in a high school science class taught by Trudy Anderson, Ed.D. “She made science exciting,” Hodges said. Two decades later, science is still fun for Hodges, who joined […]

Hhex gene critical for maintaining blood cells

Thursday, July 16th, 2015

Hhex is a gene linked to blood cancers such as T-cell and early T-cell precursor acute lymphoblastic leukemia, a treatment-resistant subtype. An Hhex knockout mouse model would be invaluable for understanding the genetic basis of T-cell leukemias and finding possible treatments. However, Hhex is critical for embryonic development and conventional Hhex knockout mice do not survive […]

VICC, Incyte collaborate to study cancer therapies

Thursday, July 9th, 2015

Vanderbilt-Ingram Cancer Center (VICC) has entered into a multi-year research support and collaboration agreement with Incyte Corporation. The agreement will support basic and translational research to enable novel therapeutic approaches for patients with cancer. See press release.  

NCI report shows U.S. cancer deaths on decline

Thursday, April 2nd, 2015

The death rates for most forms of cancer continue to decline at a modest pace among men, women and children in the United States, according to the Annual Report to the Nation on the Status of Cancer 1975 – 2011. The report from the National Cancer Institute, a division of the National Institutes of Health, […]

Exploring myeloma treatment’s impact on heart

Thursday, February 5th, 2015

  Vanderbilt is embarking on an observational study to define and understand how a promising treatment for multiple myeloma affects the heart. The Prospective Observation of Cardiac Safety with Proteasome Inhibition (PROTECT) trial capitalizes on the collaborative relationship between Vanderbilt Heart and Vascular Institute and Vanderbilt-Ingram Cancer Center, with the goal of managing cardiac toxicity […]

Next Page »